INTRODUCTION {#s1}
============

More than 85% of patients with breast cancer (BC) live \> 5 years after diagnosis in Western countries,^[@B1]^ with a current prevalence reaching \> 3 million 5-year survivors in North America and Europe.^[@B2]^ A meta-analysis of 36 North American and European studies suggested that BC survivors were at higher risk of unemployment compared with individuals without a history of cancer.^[@B3]^ One-third of patients with BC are \< 55 years old at time of diagnosis,^[@B4]^ with several years within the workforce ahead before retirement, in an era where the legal retirement age is globally increasing.^[@B5]^ Employment issues among BC survivors are therefore a major challenge.

Return to work (RTW) after BC is a complex process that is strongly influenced by medical factors such as treatment and its related adverse events.^[@B5]-[@B8]^ Previous studies suggested that work ability could be impaired by chemotherapy,^[@B9]-[@B12]^ mastectomy,^[@B10],[@B11],[@B13]^ or axillary node dissection.^[@B12],[@B14]^ In addition, a late onset of adverse effects of BC treatment is possible for a substantial proportion of patients, and many of them experience fatigue, cognitive impairment, psychological distress, and arm dysfunction for a long time after treatment completion.^[@B15]-[@B18]^ All these effects can affect employment. Indeed, studies suggested associations of work ability with BC treatment--related adverse events such as shoulder impairment^[@B19]^ and fatigue.^[@B20],[@B21]^ In addition, psychological distress after cancer experience was also shown to adversely affect job reintegration.^[@B20],[@B21]^

Nevertheless, most of the existent evidence comes from cross-sectional studies based on small samples or from retrospective registries or administrative data with limited information on treatment.^[@B22]^ For instance, many studies lack detailed clinical information on prediagnosis comorbidities.^[@B9],[@B12],[@B20],[@B23]^ Furthermore, most studies do not evaluate different types of toxicities simultaneously and do not use validated patient-reported outcome (PRO) measures to assess physical and psychological domains. In addition, the therapy landscape for patients with early BC has changed over time, particularly during the last decade. The majority of patients now receive multimodality therapy, including new chemotherapy and endocrine therapy agents and targeted therapies such as trastuzumab.^[@B24],[@B25]^ Therefore, a clear and comprehensive assessment of the burden of contemporary BC treatment and its related toxicities on employment is lacking.^[@B22]^ Understanding the independent impact of BC treatment and its adverse effects on employment is urgently needed to better inform patients, health care providers, employers, and policy makers. The aim of this study was to identify treatment-related correlates of RTW 2 years after diagnosis, using data of a large multicenter cohort of patients with BC, including detailed information on treatment and women's health status before and after treatment.

METHODS {#s2}
=======

Data Source {#s3}
-----------

We used data of a prospective clinical cohort of patients diagnosed with stage I-III primary BC and no prior history of cancer other than basal cell skin cancer or in situ cervical carcinoma within the past 5 years (CANTO \[Cancer Toxicities\]; [NCT01993498](https://clinicaltrials.gov/ct2/show/NCT01993498)). Inflammatory BC was excluded. The cohort aimed to assess treatment-related toxicities and their psychosocial impact. Data were collected in 26 French cancer care centers. Treatment and tumor classification were extracted from medical files. Patients' medical history, prediagnosis comorbidities, and a set of physical treatment-related toxicities were collected during face-to-face health examinations by trained clinical research nurses. PROs were collected by means of validated self-reported paper questionnaires assessing physical and psychological outcomes. Socioeconomic data were gathered through an ad hoc self-reported paper questionnaire gathering items from diverse French population-based surveys.^[@B26],[@B27]^ These data were collected prospectively at 3 time points: at diagnosis (baseline); at the first post-treatment visit (T1), 3 to 6 months after the end of primary treatment; and at the second post-treatment visit (T2), which occurred on average 2 years after diagnosis (median, 23 months, interquartile range, 21-25 months; [Fig 1](#f1){ref-type="fig"}). End of primary treatment was defined as the end of primary surgery, chemotherapy, or radiotherapy, whichever came last. Anti--human epidermal growth factor receptor (HER2) therapy and hormonal therapy could be ongoing, if indicated. The study was approved by the French regulatory authorities. All patients enrolled in the study were age ≥ 18 years and provided written informed consent.^[@B28]^

![Design of the data collected and used in the analysis. (\*) Data collected during a face-to-face health examination by a trained clinical research nurse. (†) Data collected by means of self-reported paper questionnaires. (‡) Data extracted from medical files. CTCAE, Common Toxicity Criteria Adverse Events; PRO, patient-reported outcome; RTW, return to work.](JCO.19.01726f1){#f1}

Study Cohort {#s4}
------------

The study included the data of 5,801 patients enrolled in the CANTO cohort between March 21, 2012 and January 7, 2015 (first data lock). We restricted our analysis to women age \< 57 years old at time of diagnosis (N = 2,883) for women to be at least 5 years away from the French legal retirement age (62 years old) at baseline. Women with no information on work situation at baseline (n = 124), not employed at baseline (n = 401), and not treated with curative intent (patients with no surgery, n = 2) were excluded, as well as patients with evidence of local or distant recurrence or patients who died before the end of the study (n = 72). Of the 2,284 eligible patients, 124 were lost to clinical follow-up, and 286 did not report information on RTW at T2 (n = 410, 18% of eligible patients). Response rate to RTW assessment questions was associated with age, receipt of hormone therapy, and occupational class but did not differ in terms of stage, number of prediagnosis comorbidities, type of surgery or axillary dissection, or receipt of radiotherapy or chemotherapy (Appendix [Table A1](#TA.1){ref-type="table"}, online only). The final study sample included 1,874 respondents ([Fig 2](#f2){ref-type="fig"}).

![Flowchart of patient population.](JCO.19.01726f2){#f2}

Variables {#s5}
---------

Our outcome of interest was non-RTW (binary variable grouping part-time and full-time workers). Information on RTW was collected at T2.

Socioeconomic covariates measured at diagnosis included age (\< 40, 40-49, ≥ 50 years), having a partner (yes/no), and number of economically dependent children living in the household (0, 1, \> 1). As a proxy of socioeconomic status, we used income of the household (\< 2,000€, 2,000-4,000€, \> 4,000€) and women's occupational class according to the 6-category version of the French classification,^[@B29]^ which is roughly equivalent to the US classification: professionals and managers, technicians and associate professionals, clerks, manual workers, farmers, and self-employed. Because of small numbers, farmers were grouped with self-employed. Part-time and full-time employment before diagnosis were distinguished. Work-life imbalance (whether the woman gave priority to professional or personal life) at diagnosis was also assessed.

Clinical variables included stage (based on American Joint Committee on Cancer 7th edition)^[@B30]^ and prediagnosis comorbid medical conditions. The latter were evaluated using the Charlson comorbidity index^[@B31]^ (0/≥ 1) and a binary variable assessing the presence of ≥ 3 additional comorbid medical conditions not captured by the Charlson index but that can have a substantial burden on a woman's life and affect RTW (among the following medical areas: neurologic, cardiovascular, respiratory, GI, renal, hepatobiliary, endocrine, musculoskeletal, urogenital, hematologic, dermatological, psychiatric).

Treatment variables included receipt of radiotherapy (yes/no), surgery, and systemic treatments. Types of surgery (conservative, mastectomy, axillary node dissection, sentinel node dissection) and types of systemic treatment (chemotherapy, hormone therapy \[HT\], trastuzumab) were combined as described in [Table 1](#T1){ref-type="table"}, to account for different therapeutic strategies.
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Toxicities and PROs were collected at baseline and at T1. A set of physical toxicities was collected by a clinical research nurse during a face-to-face examination using the Common Toxicity Criteria Adverse Events Scale (CTCAE), version 4,^[@B32]^ and coded as severe when any grade ≥ 3 toxicity was reported. The number of severe CTCAE toxicities (reported in the following areas: cardiovascular, gynecologic, rheumatological, GI, dermatological, pulmonary, neurologic) was computed and then dichotomized (0, ≥ 1). Additional physical toxicities were assessed using 3 clinically relevant symptom subscales of the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire, breast cancer module (QLQ-BR23)^[@B33],[@B34]^ (namely: systemic therapy side effects, arm and breast morbidity). These 3 subscales were categorized as severe (yes/no) when a patient scored ≥ 40 on the respective scale.^[@B35],[@B36]^ Severe physical, emotional, and cognitive fatigue were defined using the EORTC quality of life questionnaire, fatigue module (QLQ-FA12) (score ≥ 50 on the respective scale).^[@B37]^ Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale (HADS).^[@B38]^ Both subscales were categorized into 3 categories (noncase \[0-7\], doubtful \[8-10\], case \[11-21\]). All these variables had ≤ 5% missing values except the Charlson comorbidity index, which had 7% missing values (Appendix [Table A2](#TA.2){ref-type="table"}, online only).

Statistical Analyses {#s6}
--------------------

Binary logistic regression analyses were performed to identify correlates of non-RTW. We first adjusted for treatment variables as well as clinical and socioeconomic covariates collected at diagnosis (model 1) and then additionally adjusted for CTCAE toxicities and PROs collected at T1 (model 2). We assessed pairwise correlation between the symptom-related covariates using χ^2^ test and Cramer's V and tested interactions between correlated variables. Multiple imputations were performed with the fully conditional specification method. We ran sensitivity analyses using QLQ-FA12 subscale scores as continuous variables in the absence of a validated threshold to dichotomize the continuum of scores. We also analyzed the impact of change in severe toxicities between baseline (diagnosis) and T1 for EORTC and HADS subscales.

Odds ratio (ORs) and 95% CIs were estimated. All tests were 2-sided at the 0.05 significance level. The R statistical package (version 3.2.3; R foundation, Vienna Austria) was used.

RESULTS {#s7}
=======

Cohort Characteristics {#s8}
----------------------

The mean age at diagnosis was 47 years. At diagnosis, 24.6% were professionals or managers and 39.4% were clerks ([Table 1](#T1){ref-type="table"}). A total of 30.0% of women reported comorbidities, measured by the Charlson or the additional comorbidity index. Overall, 30.1% of patients underwent mastectomy; 65.6%, 82.5%, and 15.1% of patients received chemotherapy, HT, and trastuzumab, respectively. The most prevalent combinations of local and systemic treatments were conservative surgery and sentinel node dissection (47.7%) and chemotherapy combined with HT (41.2%).

At the first post-treatment visit (T1), 15.5% of patients reported at least one severe physical CTCAE toxicity. Severe physical, cognitive, and emotional fatigue were reported by 22.8% 15.7%, and 17.8% of patients, respectively. In addition, 20.4% were anxious and 5.5% were depressed.

Two years after diagnosis (T2), 399 (21.3%) patients had not returned to work. Among them, 73.9% were on sick leave, 8.5% were unemployed and seeking work, 5.5% received disability benefit, 6.5% were retired, and 5.6% were in another situation. Among women who worked full time at diagnosis, 23.6% had become part-time employees.

Correlates of Non-RTW {#s9}
---------------------

In univariate analyses (Appendix [Table A2](#TA.2){ref-type="table"}), patients who had received combinations of treatment with trastuzumab, those who had undergone mastectomy and axillary node dissection, and those who reported severe physical or psychological symptoms were less likely to be working (*P* \< .001). In the first regression model focused on treatment characteristics (model 1, [Table 1](#T1){ref-type="table"}), odds of non-RTW were significantly increased for patients who were ≥ 50 years, those who had undergone mastectomy and axillary node dissection, and those who had received combinations of chemotherapy and trastuzumab. Odds of non-RTW were also significantly elevated among women with stage III BC, who reported prediagnosis comorbidities, worked part time at diagnosis, and had lower occupational classes or income ([Table 1](#T1){ref-type="table"}).

In a separate model that included CTCAE toxicities and PROs collected at T1 (model 2, [Table 1](#T1){ref-type="table"}), the same associations emerged as compared with model 1, although ORs were reduced among patients with ≥ 3 additional comorbid conditions and a low occupational class or income. By contrast, the ORs remained stable among patients who had undergone mastectomy and axillary dissection or patients who were treated with combinations of chemotherapy and trastuzumab (with or without HT). Physical and psychological symptoms associated with non-RTW were severe physical toxicity as per CTCAE, severe arm morbidity, anxiety, and depression. A trend toward higher odds of non-RTW was observed among patients with severe physical or emotional fatigue and severe systemic therapy adverse effects. Sensitivity analyses using different ways of coding PROs, as described in the methods, gave consistent results (data not shown). Models including the type of chemotherapy regimen (anthracycline-taxane based *v* other) yielded identical results, and no effect of the chemotherapy regimen on RTW was observed (Appendix [Table A3](#TA.3){ref-type="table"}, online only).

DISCUSSION {#s10}
==========

More than 70% of working-age women are in the labor force in Western countries.^[@B39]^ Employment after diagnosis and treatment of BC is therefore a major public health challenge.

Our study clarified the independent effect of BC treatment and its impact on employment. BC treatment is now standardized by national and international guidelines. We studied the effect of standard combinations of treatments that reflect the current different therapeutic strategies used in the treatment of nonmetastatic BC. Among local treatments, we found that only the most aggressive strategies (combination of mastectomy and node dissection) had a negative long-term impact on employment. The fact that we looked at these strategies together may explain the inconsistency of the effects previously found in the literature for mastectomy alone or axillary dissection alone.^[@B8]^ Regarding systemic treatments, chemotherapy alone was associated with non-RTW in model 1, but not in model 2, when accounting for treatment toxicities. Previous studies on RTW after BC usually included treatment or toxicities, but a few included both (notably fatigue). Over the 4 studies including both fatigue and treatment in multivariable models,^[@B21],[@B40]-[@B42]^ most of them did not find that chemotherapy was significantly associated with RTW in patients with BC.^[@B21],[@B41],[@B42]^ Our results suggest an independent effect of trastuzumab on RTW, with significantly increased odds of non-RTW for all combinations that include trastuzumab and chemotherapy (with or without HT), although, on average, patients had stopped trastuzumab 10 months before RTW was assessed (only 1 woman was still treated at T2). Combination of trastuzumab and chemotherapy is the standard of care for patients with biologically aggressive HER2-positive early BC. To our knowledge, only 2 studies on RTW after BC included trastuzumab, with no suggestion of impact of this treatment on employment, but they were based on limited samples.^[@B9],[@B43]^ Clinical studies report that trastuzumab is well tolerated by patients, with very few grade ≥ 3 toxicities, but potential persistent fatigue.^[@B44]^ It is possible that patients who receive trastuzumab for HER2-positive BC have subtle clinical late effects, but they may also be more likely to perceive themselves as sick for a longer time, being overwhelmed with fear of relapse and accumulation of treatments.

Part of the influence of treatment on RTW is due to treatment adverse effects. Although health status at diagnosis is a confounding factor in this association, many studies fail to account for prediagnosis comorbidities.^[@B20],[@B43],[@B45]-[@B47]^ Our results underline the importance of these comorbidities, which were strongly associated with RTW and were reported by 30% of the patients, even in our cohort of relatively young patients. Therefore, our results have the ability to suggest the importance of both physical and psychological symptoms at first post-treatment visit on RTW after careful control for prediagnosis comorbidities.

We investigated multiple physical and psychological symptoms. Our study, consistent with prior research, suggested that physical treatment adverse effects such as arm morbidity impact RTW through reduced work capacity.^[@B19]^ We also investigated the role of fatigue, which has been shown to have an effect on RTW of BC survivors.^[@B20],[@B21]^ In previous studies, fatigue was measured through questionnaires assessing global fatigue, combining the different aspects of fatigue (eg, physical, emotional).^[@B11],[@B20],[@B21],[@B42],[@B43]^ This is the first report, to our knowledge, separately assessing the impact of different domains of fatigue on RTW with a validated questionnaire (EORTC QLQ-FA12). Using a more granular indicator, we showed that, when taking into account multiple physical and psychological symptoms, none of the subdomains of fatigue was correlated with RTW. Still, our results show a trend for a negative impact of emotional and physical fatigue on employment after BC.

Psychological factors were also associated with RTW. These factors may be induced by cancer diagnosis, cancer symptoms, or cancer treatments; they also may preexist or be increased by cancer. Consistent with the literature, we found that anxiety and/or depression were associated with RTW.^[@B19]-[@B21]^ The literature is fragmented and rarely includes physical and psychological symptoms simultaneously, whereas our analysis included multiple symptoms showing that several physical toxicities as well as several psychological symptoms were strongly and negatively correlated with RTW. Thus, our results suggest the multidimensional aspect of RTW and the importance of accounting for various health domains.

Our results are based on a large prospective study of patients recruited in 26 different centers across France. Our study presents several strengths, namely its large sample size, its longitudinal design, and the quality of the data collected. The data included detailed information on treatment and health status before diagnosis and at first post-treatment visit. The study included physical treatment-related toxicities, collected during a face-to-face examination and through validated quality-of-life questionnaires specific to BC, and also psychological symptoms, which often were not included in previous studies.^[@B9]-[@B14],[@B46],[@B48],[@B49]^ The longitudinal design allowed us to collect those symptoms 1 year before our measure of RTW and thus to minimize bias occurring in cross-sectional design when simultaneously assessing the variable of interest and the outcome. Working conditions shown to be related to RTW, such as employer accommodation and support^[@B48],[@B50]^ or attitudes about work since diagnosis,^[@B51]^ were not assessed. Yet, occupational category or part-time employment were taken into consideration. As in any longitudinal study, our data suffer from attrition, with approximately 18% of patients lost to follow-up. This could have affected the rate of non-RTW (21%), yet it was close to the rate found in a French national population-based survey (25%).^[@B26]^ As usually observed in the literature, patients with a higher socioeconomic position were more likely to respond. The final sample was still large and allowed us to model the influence of different therapeutic strategies and of multiple physical and psychological symptoms on RTW. To our knowledge, this report is the first to include both physical and psychological symptoms and to control for prediagnosis comorbidities and socioeconomic status on such an important sample.^[@B42]^

Given the importance of employment for rehabilitation, it is essential to provide patients with BC with programs to support them in job reintegration. However, even though returning to the workplace allows many patients to maintain a sense of normalcy or control,^[@B52]^ a substantial proportion of them need to take time to recover, especially if they experience long-lasting psychological symptoms. Consistent with 2 systematic reviews investigating the effect of interventions on RTW among cancer survivors, our results highlight the need to propose multidisciplinary interventions that not only focus on vocational issues but also involve physical and psychosocial components, for helping patients with BC to reintegrate the workforce.^[@B53],[@B54]^ In particular, this comprehensive study identified potentially vulnerable patients and thus warrants additional research focusing on these patients who lag behind and on supportive interventional strategies to facilitate their RTW.

Presented at the ASCO Annual Meeting, Chicago, Illinois, May 31-June 4, 2019.

Supported by French Foundation for Cancer Research Grant No. ARC, PGA1 RF20170205420, and by Susan G. Komen Career Catalyst Research Grant No. CCR17483507 to I.V.L. and the Philanthropic Odyssea Gustave Roussy Program. The CANTO study is supported by the French Government under the Investment for the Future program managed by the National Research Agency, Grant No. ANR-10-COHO-0004.

AUTHOR CONTRIBUTIONS {#s12}
====================

**Conception and design:** Agnes Dumas, Ines Vaz Luis, Antonio Di Meglio, Sarah Dauchy, Patrick Arveux, Fabrice Andre, Gwenn Menvielle

**Financial support:** Ines Vaz Luis

**Administrative support:** Jerome Lemonnier

**Provision of study material or patients:** Suzette Delaloge, Paul Cottu, Florence Lerebours, Anne Lesur, Christelle Levy, Laurence Vanlemmens

**Collection and assembly of data:** Agnes Dumas, Ines Vaz Luis, Sandrine Pinto, Sarah Dauchy, Suzette Delaloge, Patrick Arveux, Charles Coutant, Anne Lesur, Florence Lerebours, Olivier Tredan, Laurence Vanlemmens, Christelle Levy, Jerome Lemonnier, Christelle Mesleard, Fabrice Andre, Gwenn Menvielle

**Data analysis and interpretation:** Agnes Dumas, Ines Vaz Luis, Thomas Bovagnet, Mayssam El Mouhebb, Antonio Di Meglio, Sandrine Pinto, Cecile Charles, Suzette Delaloge, Charles Coutant, Paul Cottu, Anne Lesur, Laurence Vanlemmens, Fabrice Andre, Gwenn Menvielle

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

AUTHORS\' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST {#s13}
========================================================

Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO) {#s14}
----------------------------------------------------------------------------------------------------------

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO\'s conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/journal/jco/site/ifc](https://ascopubs.org/journal/jco/site/ifc).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](https://openpaymentsdata.cms.gov/)).

Ines Vaz Luis {#s15}
-------------

**Honoraria:** Novartis, Kephren, AstraZeneca

**Consulting or Advisory Role:** Ipsen

Sarah Dauchy {#s16}
------------

**Honoraria:** MSD Oncology, Pierre Fabre, SERVIER, Novartis, MSD Oncology

**Travel, Accommodations, Expenses:** SERVIER

Suzette Delaloge {#s17}
----------------

**Consulting or Advisory Role:** AstraZeneca

**Research Funding:** AstraZeneca (Inst), Pfizer (Inst), Genentech (Inst), Puma (Inst), Eli Lilly (Inst), Novartis (Inst), Sanofi (Inst)

**Travel, Accommodations, Expenses:** Pfizer, AstraZeneca, Roche

Paul Cottu {#s18}
----------

**Honoraria:** Pfizer, Novartis, Roche, AstraZeneca, NanoString Technologies

**Consulting or Advisory Role:** Pfizer, Novartis, Genentech, Context Therapeutics

**Research Funding:** Novartis (Inst), Pfizer (Inst)

**Travel, Accommodations, Expenses:** Roche, Novartis, Pfizer, Eli Lilly

Olivier Tredan {#s19}
--------------

**Consulting or Advisory Role:** Roche, Pfizer, Novartis, Eli Lilly, AstraZeneca, MSD Oncology

**Research Funding:** Roche, Novartis, Pfizer, Eli Lilly, Bristol-Myers Squibb, MSD Oncology, AstraZeneca

**Travel, Accommodations, Expenses:** Roche, Novartis, Pfizer, Eli Lilly, AstraZeneca

Fabrice Andre {#s20}
-------------

**Research Funding:** AstraZeneca (Inst), Novartis (Inst), Pfizer (Inst), Eli Lilly (Inst), Roche (Inst), Daiichi (Inst)

**Travel, Accommodations, Expenses:** Novartis, Roche, GlaxoSmithKline, AstraZeneca

No other potential conflicts of interest were reported.

###### 

Characteristics of Respondents and Nonrespondents (N = 2,284)

![](JCO.19.01726ta1)

###### 

Factors Associated with Non-RTW at the Second Post-Treatment Visit, 2 Years After Diagnosis: Univariate Analysis (n = 1,874)
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